|
4. Scope of consolidation
Stevanato Group S.p.A. is the parent company of the Group and it holds, directly and indirectly, interests in the Group’s operating companies. The Group’s scope of consolidation at December 31, 2024 and 2023 is as follows:
Subsidiaries
The consolidated financial statements of the Group include the following companies controlled by the parent company Stevanato Group S.p.A. directly or indirectly through the subsidiaries Stevanato Group International a.s., Balda Medical GmbH and Spami S.r.l.:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
% equity interest |
Name |
|
Segment |
|
Description |
|
Country of incorporation |
|
2024 |
|
|
2023 |
Nuova Ompi S.r.l. |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production of drug containment solutions and development of integrated solutions for the pharmaceutical industry |
|
Italy |
|
100% |
|
|
100% |
Spami S.r.l. |
|
Engineering |
|
Production plant and machinery |
|
Italy |
|
100% |
|
|
100% |
Stevanato Group International a.s. |
|
Holding |
|
Service/ Subholding company |
|
Slovakia |
|
100% |
|
|
100% |
Medical Glass a.s. |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production of drug containment solutions |
|
Slovakia |
|
99.74% |
|
|
99.74% |
Stevanato Group N.A. S. de RL de CV (*) |
|
Biopharmaceutical and Diagnostic Solutions |
|
Service company |
|
Mexico |
|
|
— |
|
|
100% |
Ompi N.A. S. de RL de CV |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production of drug containment solutions |
|
Mexico |
|
100% |
|
|
100% |
Ompi of America inc. |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production and sale of drug containment solutions and analytical services |
|
USA |
|
100% |
|
|
100% |
Ompi do Brasil I. e C. de Em. Far. Ltda |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production of drug containment solutions |
|
Brazil |
|
100% |
|
|
100% |
Perugini S.r.l. |
|
Engineering |
|
Production of consumables and mechanical components for industrial machines |
|
Italy |
|
100% |
|
|
100% |
Ompi Pharm. Packing Techn. Co. Ltd |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production of drug containment solutions |
|
China |
|
100% |
|
|
100% |
Stevanato Group Denmark A/S |
|
Engineering |
|
Production plant and machinery |
|
Denmark |
|
100% |
|
|
100% |
Medirio SA |
|
Biopharmaceutical and Diagnostic Solutions |
|
Research and development |
|
Switzerland |
|
100% |
|
|
100% |
Balda Medical Gmbh |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production of in-vitro diagnostic solutions |
|
Germany |
|
100% |
|
|
100% |
Balda C. Brewer Inc. |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production of in-vitro diagnostic solutions |
|
USA |
|
100% |
|
|
100% |
Balda Precision Inc. |
|
Biopharmaceutical and Diagnostic Solutions |
|
Production metal components |
|
USA |
|
100% |
|
|
100% |
Ompi of Japan Co., Ltd. |
|
Biopharmaceutical and Diagnostic Solutions |
|
Sale of drug containment solutions |
|
Japan |
|
100% |
|
|
100% |
(*) In the fourth quarter of 2024, the liquidation process of Stevanato Group N.A. S. de RL de CV was completed with the cancellation from the local business register.
Non-controlling interests
The equity and the net profit attributable to non-controlling interests at December 31, 2024 related to Medical Glass a.s. in which the Group holds an 99.74% interest. For further details refer to Note 36.
|